To include your compound in the COVID-19 Resource Center, submit it here.

Versant, Bayer bet big on iPS cells to tackle price, efficacy of CAR therapies

Looking to tap allogeneic iPS cells to address the shortcomings of CAR cell therapies, Bayer and Versant Ventures launched Century Therapeutics on Monday with $250 million in funding.

It’s the second time the partners have teamed up to create a new company with a megaround. In 2016, Versant and Bayer AG (Xetra:BAYN) launched stem cell play BlueRock Therapeutics L.P. (Cambridge, Mass.) with a $225 million series A (see “Starting Up Stem Cells”).

Monday's news also signals Bayer's commitment

Read the full 760 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE